Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936852 | 0.96 | DGAT1 (1.00) | DGAT1MCL1GABRB2 | |
| SCHEMBL18541103 | 0.89 | DGAT1 (0.80) | DGAT1GABRB2 | |
| SCHEMBL15293975 | 0.87 | DGAT1 (0.77) | DGAT1GABRB2 | |
| SCHEMBL18541097 | 0.85 | DGAT1 (0.82) | DGAT1MCL1NPC1RAB9A | |
| SCHEMBL16660752 | 0.83 | DGAT1 (0.71) | DGAT1GABRB2 | |
| SCHEMBL18541104 | 0.82 | DGAT1 (0.70) | DGAT1 | |
| SCHEMBL16661173 | 0.82 | DGAT1 (0.69) | DGAT1GABRB2NPC1RAB9A | |
| SCHEMBL9935393 | 0.82 | DGAT1 (0.69) | DGAT1ENPP3ENPP1 | |
| SCHEMBL16787643 | 0.81 | DGAT1 (0.89) | DGAT1NPC1RAB9A | |
| SCHEMBL21064758 | 0.80 | DGAT1 (1.00) | DGAT1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-2862856-A1 | AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | DGAT1 1688/4885MCL1 2668/4885ENPP3 4854/4885 |
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | DGAT1 1688/4885MCL1 2668/4885ENPP3 4854/4885 |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | DGAT1 1688/4885MCL1 2668/4885ENPP3 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.